Dynavax DVAX Stock
Dynavax Price Chart
Dynavax DVAX Financial and Trading Overview
| Dynavax stock price | 15.5 USD |
| Previous Close | 15.5 USD |
| Open | 0 USD |
| Bid | 13.32 USD x 100 |
| Ask | 17.67 USD x 100 |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 15.73 USD |
| Volume | 0 USD |
| Avg. Volume | 3.22M USD |
| Market Cap | 1.82B USD |
| Beta (5Y Monthly) | 0.925 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16 USD |
DVAX Valuation Measures
| Enterprise Value | 1.46B USD |
| Trailing P/E | N/A |
| Forward P/E | 46.969696 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.5068383 |
| Price/Book (mrq) | 3.4058447 |
| Enterprise Value/Revenue | 4.422 |
| Enterprise Value/EBITDA | 60.365 |
Trading Information
Dynavax Stock Price History
| Beta (5Y Monthly) | 0.925 |
| 52-Week Change | 19.87% |
| S&P500 52-Week Change | 26.09% |
| 52 Week High | 15.73 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 13.85 USD |
| 200-Day Moving Average | 11.24 USD |
DVAX Share Statistics
| Avg. Volume (3 month) | 3.22M USD |
| Avg. Daily Volume (10-Days) | 2.68M USD |
| Shares Outstanding | 113.68M |
| Float | 100.34M |
| Short Ratio | 2.81 |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 101.54% |
| Shares Short | 9.79M |
| Short % of Float | 13.18% |
| Short % of Shares Outstanding | 8.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -13.13% |
| Operating Margin (ttm) | 24.76% |
| Gross Margin | 61.60% |
| EBITDA Margin | 7.32% |
Management Effectiveness
| Return on Assets (ttm) | 1.20% |
| Return on Equity (ttm) | -7.14% |
Income Statement
| Revenue (ttm) | 330.51M USD |
| Revenue Per Share (ttm) | 2.7 USD |
| Quarterly Revenue Growth (yoy) | 17.69% |
| Gross Profit (ttm) | 203.6M USD |
| EBITDA | 24.21M USD |
| Net Income Avi to Common (ttm) | -43401000 USD |
| Diluted EPS (ttm) | -0.37 |
| Quarterly Earnings Growth (yoy) | 53.00% |
Balance Sheet
| Total Cash (mrq) | 647.81M USD |
| Total Cash Per Share (mrq) | 5.52 USD |
| Total Debt (mrq) | 289.22M USD |
| Total Debt/Equity (mrq) | 54.15 USD |
| Current Ratio (mrq) | 7.622 |
| Book Value Per Share (mrq) | 4.551 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 90.63M USD |
| Levered Free Cash Flow (ttm) | 51.3M USD |
Profile of Dynavax
| Country | United States |
| State | CA |
| City | EmeryVille |
| Address | 2100 Powell Street |
| ZIP | 94608 |
| Phone | 510 848 5100 |
| Website | https://www.dynavax.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 405 |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Q&A For Dynavax Stock
What is a current DVAX stock price?
Dynavax DVAX stock price today per share is 15.5 USD.
How to purchase Dynavax stock?
You can buy DVAX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Dynavax?
The stock symbol or ticker of Dynavax is DVAX.
Which industry does the Dynavax company belong to?
The Dynavax industry is Drug Manufacturers - Specialty & Generic.
How many shares does Dynavax have in circulation?
The max supply of Dynavax shares is 117.42M.
What is Dynavax Price to Earnings Ratio (PE Ratio)?
Dynavax PE Ratio is 0.00000000 now.
What was Dynavax earnings per share over the trailing 12 months (TTM)?
Dynavax EPS is 0 USD over the trailing 12 months.
Which sector does the Dynavax company belong to?
The Dynavax sector is Healthcare.
Dynavax DVAX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}